AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing.

The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also determining the recommended dose for future studies. 177Lu-BetaBart (RV‑01) is a 177Lutetium‑conjugated monoclonal antibody engineered to target the 4Ig isoform of B7‑H3, an immune checkpoint molecule overexpressed across multiple solid tumor types.

"Enabling the first patient dose of 177Lu-BetaBart reflects what matters most to us, ensuring that high‑quality radiopharmaceuticals are manufactured, released, and delivered on time so patients can access innovative therapies without delay," said Bruno Paquin, Chief Executive Officer of AtomVie. "Our team is deeply focused on operational excellence and reliability, supporting our partners from early clinical development through global supply."

"Dosing the first patient in the Phase 1/2a clinical study of 177Lu‑BetaBart represents an important milestone for Radiopharm Theranostics," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "We appreciate AtomVie's manufacturing expertise and commitment to quality as we advance BetaBart for patients with aggressive and difficult‑to‑treat solid tumors."

About BetaBart (RV-01)

RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with BetaBart have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent.

About the Phase 1/2a Clinical Trial

The FIH Phase 1/2a study (NCT07189871) is designed to establish the safety profile, biodistribution, pharmacokinetics, and radiation dosimetry of 177Lu-Betabart . The study aims to enroll 61 eligible participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal squamous cell carcinoma.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm Theranostics is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

For more information, please contact:
Riccardo Canevari, CEO & Managing Director
Phone number: +1 862 309 0293
e-mail id: rc@radiopharmtheranostics.com

About AtomVie(AtomVie)

AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently building and commissioning a new state-of-art, purpose-built 72,300 sq ft facility, set for operational readiness in H2 2026. For additional details visit our website https://www.atomvie.com/

For more information, please contact:
Tina Chainani, Business Development Manager
Phone number: +1 437 239 1288
e-mail id: tina.chainani@atomvie.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

SHENZHEN, China, Feb. 24, 2026 /PRNewswire/ -- CNS INTERTRANS (SHENZHEN) CO., Ltd., an international freight forwarder and logistics service provider, is introducing a door-to-door global logistics service that brings sea, air, and road transport into one coordinated network. By running shipments through a single framework, the company aims to reduce handover delays that commonly slow cross-border trade.

The company now handles the entire journey from pickup at the origin through to final delivery under a single operational umbrella that covers sea freight, air transport, and inland trucking. By pulling these modes together, CNS INTERTRANS eliminates many of the headaches shippers face when juggling multiple carriers and handoffs.

The Push for Smarter Global Logistics

Unreliable schedules and port congestion have pushed shippers to rethink cargo movement across global supply chains. Flexible routes that combine sea, air, and road transport are increasingly used to avoid delays and missed deliveries.

CNS INTERTRANS focuses on smart intermodal logistics solutions. Routes can be adjusted around delivery deadlines, budget considerations, or real-time conditions at the destination—without disrupting the overall flow of cargo. That flexibility matters most in trade lanes with multiple stops and varying regulations.

One Network Linking Sea, Air, and Road Transport

Ocean shipping still carries the bulk of global freight. CNS INTERTRANS offers full container loads, special containers, roll-on/roll-off, breakbulk, and heavy-lift services, serving everyone from standard goods shippers to those moving oversized or odd-shaped loads.

When speed is critical, air freight steps in. Air freight is the go-to move when deadlines loom. CNS INTERTRANS folds those flights neatly into the sea and road transport, letting shippers shave days off transit without having to rethink their entire routing strategy.

Road transport connects everything, taking cargo from ports and airports to inland warehouses or straight to the final delivery address. Coordinated trucking and intermodal handoffs help maintain cargo continuity from gateway to doorstep.

Door-to-Door Means Handling the Whole Mess

Door-to-door logistics extends well beyond physical transport. Customs clearance, local handling at the destination, and compliance with a maze of regulations are often what make or break the timeline.

CNS INTERTRANS bundles customs brokerage, destination services, and warehousing into the package. Fewer handovers mean better visibility and fewer surprises throughout the process—especially helpful in cross-border trade and time-sensitive project cargo.

Handling Complex Project Cargo

Some industries need far more than standard containers. CNS INTERTRANS specializes in project logistics for heavy machinery, oversized equipment, and non-standard loads.

Special containers, breakbulk transportation, and RO-RO shipping options, combined with custom routing and equipment planning, support major infrastructure builds, industrial exports, and large-scale equipment moves.

Adapting to Evolving Global Trade Demands

Logistics buyers today want partners who can run an entire multimodal network, not just pieces of it. The ability to combine sea, air, and road under one roof has become a must-have for building resilient supply chains.

By tying these transport modes together, CNS INTERTRANS is ready to handle whatever new trade patterns and challenges come next.

About CNS INTERTRANS

Founded in 2005, CNS INTERTRANS is an international freight forwarder and logistics provider offering door-to-door global logistics services through integrated sea, air, and road networks. Its capabilities include container shipping, special containers, project logistics, breakbulk and heavy cargo handling, customs clearance, destination services, and warehousing.

Media Contact:
Company: CNS INTERTRANS (SHENZHEN) CO., Ltd.
Website: https://www.cnslogistic.com/
WhatsApp: +86-18002569199
Email: zuojianye@cnslogistic.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

CNS INTERTRANS Provides Door-to-Door Global Logistics Solutions Through Integrated Sea, Air and Road Networks